Search results for "Editorial Comments"

showing 2 items of 2 documents

Microsatellite Instability in Colorectal Cancer: Time to Stop Hiding!

2011

Colorectal cancer (CRC) is the second cause of cancer-related death worldwide. Surgery constitutes the primary therapy for these tumors, together with chemotherapy that is usually recommended in patients with metastatic primary CRC. Although molecularly distinct entities arising from different physiopathogenic mechanisms - microsatellite (MSI) and chromosomal instability (also called microsatellite stable, MSS) - have been characterized in CRC, there is still no specific therapeutic approach that takes into account disease’s molecular heterogeneity [1]. MSI is observed in 1015% of sporadic CRCs. MSI CRCs displayed particular morphologic features, with greater predilection for the right colo…

Pathologymedicine.medical_specialtyChemotherapyColorectal cancermedicine.medical_treatmentMicrosatellite instabilityDiseaseBiologymedicine.diseasedigestive system diseasesTherapeutic approachOncologyChromosome instabilityCancer researchmedicineMicrosatelliteAnimalsHumansIn patientMicrosatellite InstabilityHSP110 Heat-Shock ProteinsColorectal NeoplasmsneoplasmsEditorial CommentsOncotarget
researchProduct

SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia

2020

Abstract Sodium–glucose co-transporter-2 (SGLT2) inhibitors decreased cardiovascular (CV) events and improved renal outcomes in CV safety studies in type 2 diabetes melitus (T2DM) patients at high CV risk. Canagliflozin also improved kidney outcomes in diabetic kidney disease in the Canagliflozin and Renal Events in Diabetes and Nephropathy Clinical Evaluationtrial. More recently, the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) trial showed that dapagliflozin improved CV outcomes in patients with HF with or without diabetes. Protection from HF in non-diabetics was confirmed for empagliflozin in the EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Fa…

medicine.medical_specialty030232 urology & nephrologyUrologyRenal functionType 2 diabetes030204 cardiovascular system & hematologyoutcomesNephropathy03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDiabetes mellitusClinical endpointMedicineDapagliflozinAcademicSubjects/MED00340Editorial CommentsCanagliflozinTransplantationclinical trialsbusiness.industrySGLT2 inhibitormedicine.diseasemortalitychemistryNephrologybusinesschronic kidney diseaseKidney diseasemedicine.drugClinical Kidney Journal
researchProduct